SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) is presenting new data this week on an experimental drug candidate, HE3286, an orally active novel synthetic steroid hormone. Highlights from the presentation include findings demonstrating HE3286 had a dramatic benefit in a rodent model of rheumatoid arthritis. In a collagen-induced arthritis model (CIA), HE3286, when compared to placebo, significantly reduced the severity of disease and decreased disease over the course of the study. Moreover, histological analysis of joint tissue conducted at the end of the study indicated a marked reduction of tissue damage in the HE3286-treated animals compared to placebo. The findings are being presented this week in a series of oral presentations at the Fifth International Congress on Autoimmune Diseases being held in Sorrento, Italy.
